Volume 95 Issue 28 | p. 15 | Concentrates
Issue Date: July 10, 2017

GSK in computing pact with Exscientia

Department: Business
Keywords: Drug discovery, artificial intelligence, machine learning, GSK

GlaxoSmithKline has partnered with Exscientia to use artificial intelligence to develop small molecules against up to 10 drug targets. Exscientia seeks to use AI to design molecules with a desired balance of potency, selectivity, and pharmacokinetics. GSK will provide the firm with research funding and up to $42 million in milestone payments as molecules reach preclinical studies. In May, Exscientia joined with Sanofi to develop bispecific small molecules against metabolic diseases targets.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment